| Document |
Document Title |
|
WO/2021/074782A1 |
An ophthalmic solution based on hyaluronic acid and arabinogalactan in synergistic amounts is used, alone or in combination with panthenol, vitamin E-D-α—polyethylene-glycol (TGPS) and trehalose, in the treatment of dry-eye syndrome, ...
|
|
WO/2021/075536A1 |
The present disclosure provides a therapy for diabetes that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases a...
|
|
WO/2021/071864A1 |
Provided herein are pharmaceutical compositions comprising a bacterial consortium and one or more pharmaceutically acceptable excipients. Such pharmaceutical compositions can be orally administered to a subject for prevention and/or trea...
|
|
WO/2021/069523A1 |
The present invention relates to therapeutic use of calreticulin in treatment of angiogenic eye diseases. Different treatment methods and pharmaceutical compositions comprising calreticulin are disclosed.
|
|
WO/2021/071835A1 |
Provided herein are pharmaceutical compositions comprising a recombinant adeno-associated virus (AAV), salt excipient or buffer agent, sugar and surfactant. Also provided herein are methods for treating or preventing a disease in a subje...
|
|
WO/2021/069750A1 |
A system for and method of monitoring/measuring the level of receptoral action/blockade and intra-ocular penetration/concentration of an eye medication and determining an optimal treatment regime based on the level of receptoral action/b...
|
|
WO/2021/068203A1 |
Use of chloroquine or a derivative thereof hydroxychloroquine in the preparation of a medicament for the treatment of Graves' oculopathy. Chloroquine or the derivative thereof hydroxychloroquine has a significant inhibitory effect on the...
|
|
WO/2021/069553A1 |
The current invention concerns liver progenitor or stem cells, lysates thereof, and/or conditioned medium obtainable by culturing liver progenitor or stem cells in said medium for use in the treatment of diseases and/or conditions caused...
|
|
WO/2021/071413A1 |
A yeast cell for use in the treatment and/or alleviation of allergy and/or symptoms caused by allergy, wherein the yeast cell has been treated with electromagnetic waves in the range of 1 GHz to 300 GHz, or said yeast cell has been grown...
|
|
WO/2021/070181A1 |
The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers.
|
|
WO/2021/072265A1 |
Provided herein are methods of treating eye disorders by administering an anti-VEGF antibody and/or conjugate to a subject having an eye disorder. The anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate th...
|
|
WO/2021/065050A1 |
The purpose of the present invention is to provide a formulation technique pertaining to an aqueous liquid formulation that contains brimonidine and/or a salt thereof. This aqueous liquid formulation contains brimonidine and/or a salt ...
|
|
WO/2021/066144A1 |
This disclosure provides a means for treating dry eye. This disclosure can provide: a composition for treating dry eye; and a use thereof. The composition includes (E) -2-(7-trifluoromethyl-chroman-4-yllidene)-N-(7-hydroxy-5,6,7
,8-tet...
|
|
WO/2021/066672A1 |
The inventions relate to the pharmaceutical and medical industry and are applicable in medicine, and more particularly relate to the use of a biologically active extract of the plant Alhagi pseudalhagi for new purposes and to a pharmaceu...
|
|
WO/2021/062007A1 |
The present disclosure provides a method of treating mitochondrial and age-related diseases and disorders with exercised blood products. The blood products include circulating factors whose production or secretion into the blood is stimu...
|
|
WO/2021/058636A1 |
The present invention relates to antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). More specifically, anti-Nrp1A antibodies and methods of use for the treatment of various diseases or disorders are disclo...
|
|
WO/2021/061980A1 |
Compositions, methods, and kits are provided for diagnosing and treating uveitis. In particular, biomarkers have been identified that can be used to distinguish infectious uveitis from noninfectious uveitis, and further discriminate amon...
|
|
WO/2021/061000A1 |
The subject-matter of the invention is a composition of a dietary supplement and/or a nutritional additive for food, a unitary dosage form of said composition, and their use for the improvement of the quality of visual performance includ...
|
|
WO/2021/061823A1 |
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibi...
|
|
WO/2021/060460A1 |
Provided are a novel repair agent for biological tissue damage, having a markedly higher repairing effect on biological tissue damage than a conventional repairing agent for biological tissue damage, and a method for manufacturing said r...
|
|
WO/2021/055013A1 |
This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. In addition, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflow...
|
|
WO/2021/051149A1 |
A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independentl...
|
|
WO/2021/052926A1 |
The present invention provides a non-natural polypeptide for use in treatment and/or prevention of an ophthalmic disorder in a mammalian subject. Administration of the polypeptide is well tolerated by the mammal. The non-natural polypept...
|
|
WO/2021/050980A1 |
This invention relates to novel method of treating or ameliorating a retinal disease or disorder or retinal degradation in a subject and a novel method of restoring retinal pigment epithelium cell compromising the administration of a one...
|
|
WO/2021/048620A1 |
The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for tre...
|
|
WO/2021/049634A1 |
Provided are: a nucleic acid that includes a nucleic acid sequence for encoding a signal sequence and a nucleic acid sequence for encoding a chimeric protein including at least a portion of ion transport receptor rhodopsin and at least a...
|
|
WO/2021/048618A1 |
The present invention relates to compounds of formula (I) that are capable of modulating, e.g., inhibiting or activating, one or more kinases, especially LRRK2 and/or NUAK1 and/or TYK2 or mutants thereof. The compounds are useful for tre...
|
|
WO/2021/049504A1 |
The present invention provides: a conjugate of an oligonucleotide having a nucleotide sequence that is expected to have a pharmacological effect in a hepatic parenchymal cell and a biantennary GalNAc unit, or a pharmaceutically acceptabl...
|
|
WO/2021/047464A1 |
The present invention relates to a use of 4-[9-(6-aminopurinyl)]-2(S)-hydroxymethyl butyrate for preparing ophthalmic preparations, and more specifically relates to a use of 4-[9-(6-aminopurinyl)]-2(S)-hydroxymethyl butyrate for preparin...
|
|
WO/2021/050094A1 |
Provided are methods for treating an ocular neovascular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles compris...
|
|
WO/2021/049864A1 |
The present invention relates to a composition which is for ameliorating dry eye syndrome and contains an aralia elata extract. A composition according to the present invention has almost no toxicity or side effects, and can thus be used...
|
|
WO/2020/165839A9 |
The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitr
ile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also prov...
|
|
WO/2021/048806A1 |
A method is provided for treating a patient having a neovascular ocular disease.
|
|
WO/2020/165838A9 |
The present invention provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitr
ile (compound I). The present invention also provides methods for treating dry eye dise...
|
|
WO/2021/050649A1 |
Provided are methods for treating an ocular neovascular disease in an individual, comprising administering a unit dose of recombinant adeno-associated virus (rAAV) particles to an eye of the individual, wherein the rAAV particles compris...
|
|
WO/2021/049898A1 |
The present invention relates to a system for corneal cross-linking of injured corneas, treating keratoconus, or correcting vision, the system comprising: a hyaluronic acid-dye conjugate; and a contact lens including an LED light source....
|
|
WO/2021/049825A1 |
The present invention relates to a nanoemulsion ophthalmic composition and a preparation method thereof, wherein the nanoemulsion ophthalmic composition is obtained by mixing cyclosporine, castor oil, hydrophilic and hydrophobic emulsifi...
|
|
WO/2021/045606A1 |
The present invention relates to ophthalmic compositions in the form of oil-in-water (O/W) nanoemulsions and which mainly comprise propylene glycol and sodium hyaluronate. The invention also relates to preparation methods and uses of the...
|
|
WO/2021/042193A1 |
The present description relates to methods of treatment and pharmaceutical compositions comprising a Nitric Oxide Synthase-inducer peptide, PnPP-19. Although usable for other purposes, the composition comprising PnPP-19 is useful for tre...
|
|
WO/2021/043723A1 |
The present invention relates to an agent for increasing PAX6 gene and/or protein expression in a subject in need thereof. The insertion of a nonsense mutation found in patients allowed inventors to identify altered gene expression of PA...
|
|
WO/2021/044045A1 |
The invention provides pharmaceutical compositions comprising cyclosporine dissolved in a semifluorinated alkane for use in the treatment of uveitis.
|
|
WO/2021/045569A1 |
The present invention relates to a composition comprising a bilberry extract as an active ingredient for preventing or treating sensorineural hearing impairment. The bilberry extract was found to exhibit effects of inhibiting the apoptos...
|
|
WO/2021/041951A1 |
This document provides AAVs and methods and materials for making and using AAVs. For example, AAVs containing a capsid polypeptide that includes an amino acid segment having a DPIVMIDNDKPIT sequence (or a variant thereof) are provided. T...
|
|
WO/2021/036975A1 |
Disclosed are a peptide amide compound composition, a preparation method therefor and medical use thereof. Specifically, the composition contains a compound of formula (I) and pH regulators, and the pH of the solution thereof is 3-5.5. T...
|
|
WO/2021/041373A1 |
Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody ("mAh") or the antigen-binding fragment of a mAh against human vascular endothelial growth factor ("hVEGF"...
|
|
WO/2021/037007A1 |
Provided in the present invention is a PD-L1 immunosuppressant, and specifically provided are a monoclonal antibody capable of targeting PD-L1, and nucleotides, combinations of polynucleotides, expression vectors and combinations of expr...
|
|
WO/2021/039748A1 |
The present invention pertains to diquafosol or a salt thereof, and an aqueous ophthalmic composition containing polyvinylpyrrolidone. The present invention further pertains to an aqueous ophthalmic composition for preventing or treating...
|
|
WO/2021/039932A1 |
The present invention relates to a method for diagnosing relapsing-remitting multiple sclerosis, the method comprising a step for measuring the relative abundance of bacteria in a stool sample collected from a test subject, and a step fo...
|
|
WO/2021/039833A1 |
The present invention addresses the problem of providing a novel means for preventing the inhibition of the proliferation of keratinocytes even when the keratinocytes begin to contact with each other. The present invention can solve th...
|
|
WO/2021/038279A1 |
The present invention could be used in medicine and relates to a method of producing ion-exchange polymeric hydrogels for eye treatment, which includes monomer copolymerization under ionizing radiation in presence of linking agent and io...
|
